Zobrazeno 1 - 10
of 871
pro vyhledávání: '"L, Del Valle"'
Autor:
Oscar Claudio-Ares, Jeileen Luciano-Rodríguez, Yolmarie L. Del Valle-González, Selene L. Schiavone-Chamorro, Alex J. Pastor, Javier O. Rivera-Reyes, Carmen L. Metzler, Lizandra M. Domínguez-Orona, Brenda Lee Vargas-Pérez, Rachid Skouta, Arthur D. Tinoco
Publikováno v:
Inorganics, Vol 12, Iss 1, p 26 (2024)
The discovery of regulated cell death (RCD) revolutionized chemotherapy. With caspase-dependent apoptosis initially being thought to be the only form of RCD, many drug development strategies aimed to synthesize compounds that turn on this kind of cel
Externí odkaz:
https://doaj.org/article/3b880c2711de4e2db4716f90a1644433
Autor:
L. Ibarra-Lara, M. Sánchez-Aguilar, L. Del Valle-Mondragón, E. Soria-Castro, L.G. Cervantes-Pérez, G. Pastelín-Hernández, A. Sánchez-Mendoza
Publikováno v:
Journal of Pharmacological Sciences, Vol 144, Iss 4, Pp 218-228 (2020)
Myocardial ischemia initiates a chain of pathological conditions leading to cardiomyocyte death. Therefore, pharmacological treatment to stop ischemia-induced damage is necessary. Fibrates, have been reported to decrease inflammatory markers and to m
Externí odkaz:
https://doaj.org/article/3894e25323894ca78443dfaaeea2abf2
Autor:
J. Stalinska, E. Zimolag, NA. Pianovich, A. Zapata, A. Lassak, M. Rak, M. Dean, D. Ucar-Bilyeu, D. Wyczechowska, F. Culicchia, L. Marrero, L. Del Valle, J. Sarkaria, F. Peruzzi, BS Jursic, K. Reiss
Publikováno v:
Translational Oncology, Vol 12, Iss 7, Pp 895-907 (2019)
Anticancer effects of a common lipid-lowering drug, fenofibrate, have been described in the literature for a quite some time; however, fenofibrate has not been used as a direct anticancer therapy. We have previously reported that fenofibrate in its u
Externí odkaz:
https://doaj.org/article/220dbf6545a74b5ab39ed2380a279119
Autor:
Richard Pazdur, Ann T. Farrell, Kirsten B. Goldberg, Ruby Leong, Chao Liu, Christopher M. Sheth, Yuan-Li Shen, Donna Przepiorka, Pedro L. Del Valle, Luning Zhuang, Sriram Subramaniam, Kunthel By, Kelly J. Norsworthy
Supplementary Figure 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40f695b031ea2746b3b535c50a6f75f0
https://doi.org/10.1158/1078-0432.22472658.v1
https://doi.org/10.1158/1078-0432.22472658.v1
Autor:
Richard Pazdur, Ann T. Farrell, Kirsten B. Goldberg, Ruby Leong, Chao Liu, Christopher M. Sheth, Yuan-Li Shen, Donna Przepiorka, Pedro L. Del Valle, Luning Zhuang, Sriram Subramaniam, Kunthel By, Kelly J. Norsworthy
Supplementary Table S2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::662c2fafd3def9de60e42b7af6e56a78
https://doi.org/10.1158/1078-0432.22472652.v1
https://doi.org/10.1158/1078-0432.22472652.v1
Autor:
Richard Pazdur, Ann T. Farrell, Marjorie Shapiro, Christopher M. Sheth, Jiang Liu, Lei Nie, Donna Przepiorka, Kelly J. Norsworthy, Charles Jewell, Antonina Aydanian, Pedro L. Del Valle, Jee Eun Lee, Chia-Wen Ko, Emily Y. Jen
Supplemental Table 1 describes the adverse events with corresponding risk differences between treatment arms during induction of pivotal trial ALFA-0701.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bd7a67b15c996ac2b4ce4780a377946
https://doi.org/10.1158/1078-0432.22470144
https://doi.org/10.1158/1078-0432.22470144
Autor:
Richard Pazdur, Ann T. Farrell, Kirsten B. Goldberg, Ruby Leong, Chao Liu, Christopher M. Sheth, Yuan-Li Shen, Donna Przepiorka, Pedro L. Del Valle, Luning Zhuang, Sriram Subramaniam, Kunthel By, Kelly J. Norsworthy
Supplementary Table S1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77f7c389244ff34327770c1c37b2a2de
https://doi.org/10.1158/1078-0432.22472655
https://doi.org/10.1158/1078-0432.22472655
Autor:
Richard Pazdur, Ann T. Farrell, Marjorie Shapiro, Christopher M. Sheth, Jiang Liu, Lei Nie, Donna Przepiorka, Kelly J. Norsworthy, Charles Jewell, Antonina Aydanian, Pedro L. Del Valle, Jee Eun Lee, Chia-Wen Ko, Emily Y. Jen
Supplemental Table 4 and the accompanying text describe the grouped terms used for the adverse reactions described in Table 2 and the reasons for using grouped terms.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bfa00162775f4396f1aa89b2c0e5fca
https://doi.org/10.1158/1078-0432.22470135.v1
https://doi.org/10.1158/1078-0432.22470135.v1
Autor:
Richard Pazdur, Ann T. Farrell, Kirsten B. Goldberg, Ruby Leong, Chao Liu, Christopher M. Sheth, Yuan-Li Shen, Donna Przepiorka, Pedro L. Del Valle, Luning Zhuang, Sriram Subramaniam, Kunthel By, Kelly J. Norsworthy
On November 21, 2018, the FDA approved glasdegib (Daurismo; Pfizer), a small-molecule Hedgehog inhibitor, in combination with low-dose cytarabine (LDAC) for treatment of newly diagnosed acute myeloid leukemia (AML) in adults ≥ 75 years or with como
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::caa9d058c026a5b87d84c0288f1eb1b1
https://doi.org/10.1158/1078-0432.c.6528291
https://doi.org/10.1158/1078-0432.c.6528291
Autor:
Richard Pazdur, Ann T. Farrell, Marjorie Shapiro, Christopher M. Sheth, Jiang Liu, Lei Nie, Donna Przepiorka, Kelly J. Norsworthy, Charles Jewell, Antonina Aydanian, Pedro L. Del Valle, Jee Eun Lee, Chia-Wen Ko, Emily Y. Jen
On September 1, 2017, the FDA granted approval for gemtuzumab ozogamicin (Mylotarg; Pfizer Inc.) in combination with daunorubicin and cytarabine and as a monotherapy for the treatment of adult patients with newly diagnosed CD33-positive acute myeloid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a3057e773121d0976ff70e8b3c1217f
https://doi.org/10.1158/1078-0432.c.6527439.v1
https://doi.org/10.1158/1078-0432.c.6527439.v1